DOCSLIB.ORG

The FDA Sunscreen Study: Lessons Learned and to Be Learned

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The FDA Sunscreen Study: Lessons Learned and to Be Learned The FDA Sunscreen Study: Lessons Learned and to be Learned Murali Matta, PhD Bioanalytical Lead Division of Applied Regulatory Science Office of Clinical Pharmacology U.S. Food and Drug Administration Overview • Primary Objective • Study Design • Outcomes • Results • Lessons learned • To be learned 2 Background • Sunscreens prevent sunburn - reflect or absorb ultraviolet radiation • Active ingredients are organic chemicals and some have been shown to be absorbed through human skin with detectable levels in the blood or urine • Sunscreen guidance: Nonprescription Sunscreen Drug Products - Safety and Effectiveness Data • The guidance requests the assessment of the human systemic absorption of sunscreen ingredients with a Maximal Usage Trial (MUsT) • This study is not intended to meet all requirements of MUsT studies, but will follow many of the principles to assess maximal use of a single sunscreen formulation 3 Primary Objective • To explore whether the active components of 4 sunscreen products are absorbed into the systemic circulation when a sunscreen product is applied under maximal-use conditions • Avobenzone • Oxybenzone • Octocrylene • Ecamsule 4 Tested Products Avobenzone 3% Avobenzone 3% Avobenzone 3% Avobenzone 3% Oxybenzone 6% Oxybenzone 5% Oxybenzone 4% Octocrylene 10% Octocrylene 2.35% Octocrylene 10% Octocrylene 6% Ecamsule 2% Homosalate 15% Octisalate 5% 5 Study Design • Subjects: Healthy Volunteers; 18 – 60 years • Open-label, randomized 4 group parallel study Dose: 2 mg/cm2 75% of body Duration: Every two hours, 4 doses/day; 4 days PK sample: 30 samples pre-dose to 144 h (intensive on days 1 & 4) 6 Outcomes • Primary Outcome: • Maximum plasma concentration (Cmax: Day 1 to 7) of Avobenzone • Secondary Outcome: • Maximum plasma concentration of Oxybenzone, Octocrylene and Ecamsule • Exploratory Outcomes: • Cmax on day 1 and 4 • Time at which Cmax occurs on day 1, 4 and overall • AUC on day 1, 4 and overall • Residual concentrations on each day • Half-life of each ingredient • Post-hoc Assessments: • Number and percentage of participants with plasma concentration exceeding 0.5 ng/mL on day 1 • Drug accumulation from day 1 to 4 7 Statistical Analysis • 24 participants were randomized to receive 1 of the 4 treatments • Randomization was conducted in block sizes of 4 • Not blinded due to differences in formulation types • Data was reported with standard descriptive statistics • Accumulation with repeat dosing was assessed by log-transforming AUC and maximum plasma concentration from day 1 and 4 for each ingredient 8 Demographics Demographics Study (N=24) Age, years (Mean ± SD) 35.5 ± 10.5 Race Black or African 14 (58.3 %) American White 9 (37.5 %) Asian 1 (4.2%) Body mass index, kg/m2 25.0 ± 2.9 (Mean ± SD) Body surface area, m2 1.8 ± 0.2 (Mean ± SD) Fitzpatrick skin type Type 1 0 (0.0 %) Type 2 1 (4.2%) Type 3 5 (20.8%) Type 4 4 (16.7%) Type 5 8 (33.3%) Type 6 6 (25.0%) 9 Systemic Exposure of Avobenzone Matta et al., JAMA 2019;321(21):2082-2091 10 Systemic Exposure on Day 1 Spray#1: 8h – 100% Spray#2: 8h – 83% Lotion: 8 h – 100% Cream: 8h – 83% Matta et al., JAMA 2019;321(21):2082-2091 11 Systemic Exposure of Oxybenzone Matta et al., JAMA 2019;321(21):2082-2091 12 Systemic Exposure on Day 1 100% of subjects had levels above 0.5ng/mL in 2hrs Matta et al., JAMA 2019;321(21):2082-2091 13 Systemic Exposure of Octocrylene 2.35% of Octocrylene Matta et al., JAMA 2019;321(21):2082-2091 14 Systemic Exposure on Day 1 100% of subjects in 6h Except Spray#1 Matta et al., JAMA 2019;321(21):2082-2091 15 Systemic Exposure of Ecamsule 5 of 6 participants has Cmax more than 0.5 ng/mL on day 1 Matta et al., JAMA 2019;321(21):2082-2091 16 Cmax on Day 1 versus Day 4 17 Residual Concentrations 18 Lessons Learned • Systemic exposure data of most commonly used ingredients under maximal usage conditions • 6 subjects is adequate to detect systemic exposure, but was insufficient to quantify any age related changes in absorption due to the small numbers • All the tested active ingredients in all tested products reached systemic exposures above 0.5 ng/mL – All active ingredients reached above 0.5 ng/mL on day 1 • All tested ingredients have long terminal half-lifes – Could be skin is serving as a depot 19 To be learned • Systemic exposure after a single application • Time to clear from body • Metabolites and their systemic exposures • Toxicity of these active ingredients • Systemic exposure in pediatrics • Role of covariates such as age across the population 20 Acknowledgements DARS/OCP DNDP/OND Nageswara Pilli Steven Adah Jeffry Florian Bob Gump Sergio Coelho Donna Volpe Jian Wang Robbert Zusterzeel Lesley-Anne Furlong Vikram Patel Charles Ganley David Strauss Theresa Michele DCPIII/OCP Luke Oh DPQR/OTR Yang Yang OCP Dennis Bashaw Ashraf Muhammad Issam Zineh Celia Cruz 21 22 Back Up SAP Clinical Protocol 23 Consort Diagram Enrollment Assessed for eligibility (n=88) Excluded (n=52) Not meeting inclusion criteria (n=33) Declined to participate (n=11) Out of screening window (n=8) Eligible as replacement subjects (n=12) 1:1:1:1 randomization (n=24) Allocation Cream Lotion Spray#1 Spray#2 Allocated to intervention Allocated to intervention Allocated to intervention Allocated to intervention (n=6) (n=6) (n=6) (n=6) Received (n= 6) Received (n= 6 ) Received (n= 6 ) Received (n= 6) Did not receive (n=0) Did not receive (n=0) Did not receive (n=0) Did not receive (n=0) Follow-Up Lost to follow-up (n=0) Discontinued intervention Lost to follow-up (n=0) Lost to follow-up (n=0) Lost to follow-up (n=0) (n=1) Discontinued intervention Discontinued intervention Discontinued intervention Study participant withdrew (n=0) (n=0) (n=0) due to adverse event (milia) Analysis Analyzed (n= 6) Analyzed (n= 6) Analyzed (n= 6) Analyzed (n= 6) Excluded from analysis Excluded from analysis Excluded from analysis Excluded from analysis (n=1) (n=0) (n=0) (n=0) 24.
Load more

Recommended publications
  • GAO-18-61, SUNSCREEN: FDA Reviewed Applications For
    United States Government Accountability Office Report to Congressional Committees November 2017 SUNSCREEN FDA Reviewed Applications for Additional Active Ingredients and Determined More Data Needed GAO-18-61 November 2017 SUNSCREEN FDA Reviewed Applications for Additional Active Ingredients and Determined More Data Needed Highlights of GAO-18-61, a report to congressional committees Why GAO Did This Study What GAO Found Using sunscreen as directed with other The Food and Drug Administration (FDA), within the Department of Health and sun protective measures may help Human Services, implemented requirements for reviewing applications for reduce the risk of skin cancer—the sunscreen active ingredients within time frames set by the Sunscreen Innovation most common form of cancer in the Act, which was enacted in November 2014. For example, the agency issued a United States. In the United States, guidance document on safety and effectiveness testing in November 2016. sunscreen is considered an over-the- counter drug, which is a drug available As of August 2017, all applications for sunscreen active ingredients remain to consumers without a prescription. pending after the agency determined more safety and effectiveness data are Some sunscreen active ingredients not needed. By February 2015, FDA completed its initial review of the safety and currently marketed in the United States effectiveness data for each of the eight pending applications, as required by the have been available in products in act. FDA concluded that additional data are needed to determine that the other countries for more than a ingredients are generally recognized as safe and effective (GRASE), which is decade. Companies that manufacture needed so that products using the ingredients can subsequently be marketed in some of these ingredients have sought the United States without FDA’s premarket approval.
    [Show full text]
  • New Technology Provides Cosmetically Elegant Photoprotection Zoe Diana Draelos, MD; Christian Oresajo; Margarita Yatskayer; Angelike Galdi; Isabelle Hansenne
    COSMETIC CONSULTATION New Technology Provides Cosmetically Elegant Photoprotection Zoe Diana Draelos, MD; Christian Oresajo; Margarita Yatskayer; Angelike Galdi; Isabelle Hansenne he primary preventable cause of photoaging is United States, as there is no official rating system for exposure to UVA radiation. This wavelength UVA photoprotection yet. T emitted by the sun is present year round in all Ecamsule absorbs UVA radiation in the range of 320 to latitudes. Currently, the majority of sun-protective prod- 360 nm, but its peak absorbance occurs at 345 nm. It is ucts provide excellent UVB protection with minimal UVA typically combined with other organic sunscreen ingredi- protection. Although UVB protection is important in ents, such as avobenzone and octocrylene. Avobenzone, order to prevent sun damage to the skin from occurring, which is a photounstable photoprotectant, becomes UVA protection is equally important. New developments photostable when combined with octocrylene. These in raw material science have led to the manufacture of ingredients yield a photostable broad-spectrum sunscreen novel ingredients able to provide unprecedented photo- combination. However, the active sunscreen agents are protection COSin the UVA spectrum. DERMonly part of the formulation. Also important in sunscreen One of the most significant developments in cutaneous is the construction of the vehicle to deliver the photo- UVA protection was the discovery of ecamsule (Figure 1), protectants in an aesthetically pleasing manner, enticing also known as Mexoryl SX. Mexoryl SX, which has patients to wear the product. Sunscreens fail to be effec- the International Nomenclature of Cosmetic Ingredients tive if they remain in the bottle. name of terephthalylidene dicamphor sulfonic acid, is In order to evaluate the efficacy and tolerability of a water soluble.
    [Show full text]
  • 1. Background and Action Requested
    June 27, 2019 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Comments Submitted to Docket No. 1978N-0018 (Formerly Docket No. FDA–1978–N– 0038) for “Sunscreen Drug Products for Over-the-Counter Human Use,” Regulatory Information No. 0910-AF43 DSM Nutritional Products LLC (“DSM”) is pleased to provide the following comments in response to the Food and Drug Administration’s (FDA’s) Tentative Final Monograph (“TFM”) for Sunscreen Drug Products Over-the-Counter (OTC) Human Use, published at 84 Fed. Reg. 6204 (February 26, 2019). As a global science-based company active in Nutrition, Health and Sustainable Living, DSM is a world leading supplier of vitamins, feed, food, pharmaceutical, cosmetic, personal care and aroma ingredients. In sunscreens, DSM is a leading world-wide provider of numerous UV filters, including Avobenzone. DSM takes human health and safety very seriously and believes that sunscreens are proven and effective interventions that help provide consumer protection against skin cancers and skin damage caused by the sun’s rays. DSM is committed to proactively supporting the safety and availability of existing and new sunscreen active ingredients that help protect public health. DSM requests that FDA modify its proposed rule taking into consideration the comments provided herein. 1. Background and Action Requested Skin cancer is a significant, and largely preventable, public health concern. Sunscreens have been widely and safely used by the general public for their photoprotective properties, including prevention of photocarcinogenesis and photoaging and management of photodermatoses for more than 40 years. FDA’s Sunscreen Monograph rule has identified the permitted active ingredients (UV-filters) for sunscreens since 1978.
    [Show full text]
  • FDA Proposes Sunscreen Regulation Changes February 2019
    FDA Proposes Sunscreen Regulation Changes February 2019 The U.S. Food and Drug Administration (FDA) regulates sunscreens to ensure they meet safety and eectiveness standards. To improve the quality, safety, and eectiveness of sunscreens, FDA issued a proposed rule that describes updated proposed requirements for sunscreens. Given the recognized public health benets of sunscreen use, Americans should continue to use broad spectrum sunscreen with SPF 15 or higher with other sun protective measures as this important rulemaking eort moves forward. Highlights of FDA’s Proposals Sunscreen active ingredient safety and eectiveness Two ingredients (zinc oxide and titanium dioxide) are proposed to be safe and eective for sunscreen use and two (aminobenzoic acid (PABA) and trolamine salicylate) are 1 proposed as not safe and eective for sunscreen use. FDA proposes that it needs more safety information for the remaining 12 sunscreen ingredients (cinoxate, dioxybenzone, ensulizole, homosalate, meradimate, octinoxate, octisalate, octocrylene, padimate O, sulisobenzone, oxybenzone, avobenzone). New proposed sun protection factor Sunscreen dosage forms (SPF) and broad spectrum Sunscreen sprays, oils, lotions, creams, gels, butters, pastes, ointments, and sticks are requirements 2 proposed as safe and eective. FDA 3 • Raise the maximum proposed labeled SPF proposes that it needs more data for from SPF 50+ to SPF 60+ sunscreen powders. • Require any sunscreen SPF 15 or higher to be broad spectrum • Require for all broad spectrum products SPF 15 and above, as SPF increases, broad spectrum protection increases New proposed label requirements • Include alphabetical listing of active ingredients on the front panel • Require sunscreens with SPF below 15 to include “See Skin Cancer/Skin Aging alert” on the front panel 4 • Require font and placement changes to ensure SPF, broad spectrum, and water resistance statements stand out Sunscreen-insect repellent combination 5 products proposed not safe and eective www.fda.gov.
    [Show full text]
  • Kroger Co Disclaimer: Most OTC Drugs Are Not Reviewed and Approved by FDA, However They May Be Marketed If They Comply with Applicable Regulations and Policies
    SUNSCREEN- avobenzone, homosalate, octisalate, octocrylene, oxybenzone lotion The Kroger Co Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies. ---------- Kroger 711 Active Ingredients Avobenzone 3% Homosalate 13% Octisalate 5% Octocrylene 7% Oxybenzone 4% Purpose Sunscreen Use helps prevent sunburn if used as directed with other sun protections measures (see Directions), decreases the rist of skin cancer and early skin aging caused by the sun Warnings For external use only Do not use on damaged or broken skin When using this product keep out of eyes. Rinse with water to remove Stop use and ask a doctor if rash occurs Keep out of reach of children if swallowed, get medical help or contact a Poison Control Center right away Directions apply liberally 15 minutes before sun exposure reapply: after 80 minutes of swimming or sweating immediately after towel drying at least every 2 hours ​Sun Protection Measures. ​Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk use a reqularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m. - 2 p.m. wear long-sleeved shirts, pants, hats and sunglasses children under 6 months of age: Ask a doctor Other Information Protect the product from excessive heat and direct sun Inactive ingredients water, sorbitol, triethanolamine, VP/eicosene copolymer, stearic acid, sorbitan isostearate, aluminum starch octenylsuccinate, benzyl alcohol, dimethicone, tocopheryl, chlorphenesin, polyglyceryl-3 distearate, fragrance, carbomer, disodium EDTA Questions or comments? 1-800-632-6900 Adverse Reaction DISTRIBUTED BY THE KROGER CO.
    [Show full text]
  • WO 2013/036901 A2 14 March 2013 (14.03.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/036901 A2 14 March 2013 (14.03.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 8/30 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2012/054376 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 10 September 2012 (10.09.2012) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 61/532,701 9 September 201 1 (09.09.201 1) US (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): UNIVER¬ kind of regional protection available): ARIPO (BW, GH, SITY OF FLORIDA RESEARCH FOUNDATION, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, INC.
    [Show full text]
  • Les Filtres UV Dans Les Cosmétiques : Une Présence Obligatoire ?
    UNIVERSITÉ DE NANTES UFR SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES ____________________________________________________________________________ ANNÉE 2015 N° THÈSE pour le DIPLÔME D’ÉTAT DE DOCTEUR EN PHARMACIE par Anouk POCHAT Présentée et soutenue publiquement le 14 décembre 2015 Les filtres UV dans les cosmétiques : une présence obligatoire ? Président : Mme Laurence Coiffard, Professeur des universités, Laboratoire de Pharmacie industrielle et Cosmétologie Membres du jury : Directeur de thèse : Mme Céline Couteau, Maître de conférences, HDR, Laboratoire de Pharmacie industrielle et Cosmétologie Mme Françoise PEIGNE , Maitre de conférences à la retraite Page 1 Remerciements A mon président de jury, Professeur à la faculté des sciences pharmaceutiques de Nantes J’exprime mes profonds remerciements à Mme Coiffard, pour m’avoir fait l’honneur de présider mon jury de thèse. A mon directeur de thèse, Maître de conférences à la faculté de Pharmacie de Nantes Je remercie Mme Couteau pour m’avoir conseillée et guidée tout au long de mon travail. A Madame Françoise PEIGNE, Docteur en Pharmacie, Je remercie Mme Peigné d’avoir accepté d’assister à ma soutenance. A ma mère, Je te remercie de m’avoir soutenue et encouragée tout au long de mes études. A mon conjoint, Je te remercie pour ta patience, ton écoute et ton soutien. A mes frères, Je vous remercie pour vos encouragements Page 2 I.Introduction Une exposition prolongée aux UVA et aux UVB peut avoir de graves conséquences sur la santé comme, par exemple, la survenue de cancers cutanés (Aubin F., 2001). Les filtres UV permettent d’assurer une protection dans les domaines UVA et/ou UVB. On en trouve dans les produits de protection solaire que le public utilise ponctuellement lors des expositions prolongées au soleil.
    [Show full text]
  • OSEQUE ZSOLE DUAL SUN BLOCK- Octinoxate Avobenzone Bisoctrizole Spray SONGHAK CO., LTD
    OSEQUE ZSOLE DUAL SUN BLOCK- octinoxate avobenzone bisoctrizole spray SONGHAK CO., LTD. ---------- Active ingredients: Octyl Methoxycinnamate 7.5%, Ethylhexyl Salicylate 5%, Avobenzone 2%, Bisoctrizole 0.5% Purpose: Sunscreen Inactive Ingredients: Water, Alcohol Denat, Butylene Glycol, Glycerin, Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, Niacinamide, Isononyl Isononanoate, Glacier Water, Butyloctyl Salicylate, Xanthan Gum, Decyl Glucoside, Disodium EDTA, Methylparaben, Propylparaben, Fragrance Do not use: on wounds, rashes, dermatitis or damaged skin Keep out of reach of children. In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately Stop use: Please stop using this product and contact a dermatologist 1. If allergic reaction or irritation occurs 2. If direct sunlight affects the area as above When using this product: Do not use other than directed Warnings: For external use only. Not to be swallowed. Avoid contact with eyes. Discontinue use if signs of irritation or rash appear Uses: Spray or apply liberally over the face and body 15 minutes prior to sun exposure. Always ensure total coverage of all sun exposed areas. Re-apply every 1-2 hours and always after swimming. For spray type, shake it well before use and spray it evenly at 20cm-30cm apart from face or wherever needed. For spray type - shake it well before use For lotion type - turn a cap to use Storage: Keep in a dry or room temperature area OSEQUE ZSOLE DUAL SUN BLOCK octinoxate avobenzone bisoctrizole spray Product
    [Show full text]
  • Annex VI, Last Update: 02/08/2021
    File creation date: 03/10/2021 Annex VI, Last update: 22/09/2021 LIST OF UV FILTERS ALLOWED IN COSMETIC PRODUCTS Substance identification Conditions Wording of Reference Maximum conditions of Product Type, concentration Update date number Chemical name / INN / XAN Name of Common Ingredients Glossary CAS Number EC Number Other use and body parts in ready for use warnings preparation 2 N,N,N-Trimethyl-4-(2-oxoborn-3-ylidenemethyl CAMPHOR BENZALKONIUM 52793-97-2 258-190-8 6% 15/10/2010 ) anilinium methyl sulphate METHOSULFATE 3 Benzoic acid, 2-hydroxy-, HOMOSALATE 118-56-9 204-260-8 10% 02/08/2021 3,3,5-trimethylcyclohexyl ester / Homosalate 4 2-Hydroxy-4-methoxybenzophenone / BENZOPHENONE-3 131-57-7 205-031-5 6% Reg (EU) Not more than Contains 02/08/2021 Oxybenzone 2017/238 of 10 0,5 % to protect Benzophenone-3 February 2017- product (1) date of formulation application from September 2017 6 2-Phenylbenzimidazole-5-sulphonic acid and its PHENYLBENZIMIDAZOLE SULFONIC 27503-81-7 248-502-0 8%(as acid) 08/03/2011 potassium, sodium and triethanolamine salts / ACID Ensulizole 7 3,3'-(1,4-Phenylenedimethylene) bis TEREPHTHALYLIDENE DICAMPHOR 92761-26-7 / 410-960-6 / - 10%(as acid) 26/10/2010 (7,7-dimethyl-2-oxobicyclo-[2.2.1] SULFONIC ACID 90457-82-2 hept-1-ylmethanesulfonic acid) and its salts / Ecamsule 8 1-(4-tert-Butylphenyl)-3-(4-methoxyphenyl) BUTYL 70356-09-1 274-581-6 5% 15/10/2010 propane-1,3-dione / Avobenzone METHOXYDIBENZOYLMETHANE 9 alpha-(2-Oxoborn-3-ylidene)toluene-4-sulphoni BENZYLIDENE CAMPHOR SULFONIC 56039-58-8 - 6%(as acid)
    [Show full text]
  • Should a Toxicological Risk Assessment of Ubiquitous Chemicals Be Done Using Data from Only One Source of Exposure?
    Mini Review Open Acc J of Toxicol Volume 4 Issue 2 - January 2020 Copyright © All rights are reserved by Di Nardo JC DOI: 10.19080/OAJT.2020.04.555633 Should a Toxicological Risk Assessment of Ubiquitous Chemicals Be Done Using Data from Only One Source of Exposure? Di Nardo JC1* and CA Downs2 1Retired Toxicologist, Vesuvius, USA 2Executive Director, Haereticus Environmental Laboratory, Clifford, USA Submission: January 09, 2020; Published: January 23, 2020 *Corresponding author: Di Nardo JC, Retired Toxicologist, Vesuvius, USA Keywords: Toxicological; Chemicals; Dioxybenzone; Octocrylene; Oxybenzone; Sulisobenzone Introduction consumers to believe that there is no further risk associated with the After much discussion and petitioning by several individuals, chemical. non-governmental organizations and scientists alike, the Food & Drug Administration (FDA) re-opened the sunscreen drug monograph Data on February 26, 2019 to review the safety of sunscreen actives In October of 2018 the Food & Drug Administration (FDA) banned considered Generally Recognized as Safe and Effective (GRASE) the chemical benzophenone from use in foods and/or in plastic food since 1978 [1]. After their review, the FDA concluded that the public wraps [3], because it was found to cause cancer in rodents according to a study conducted by the National Institute of Environmental safety of a dozen drug actives currently in use (several of which record “does not” currently contain sufficient data to support the Health Sciences in May 2007 [3]. In June 2012 the state of California are benzophenone based chemicals - avobenzone, dioxybenzone, added benzophenone to their Proposition 65 list recognizing it as octocrylene, oxybenzone and sulisobenzone) and, therefore, are a carcinogen and came to an agreement that a sunscreen product requesting industry to provide additional data (mainly toxicokinetics, should not contain any more that 50 parts per million [4].
    [Show full text]
  • Salicylate UV-Filters in Sunscreen Formulations Compromise the Preservative System Efficacy Against Pseudomonas Aeruginosa and Burkholderia Cepacia
    cosmetics Article Salicylate UV-Filters in Sunscreen Formulations Compromise the Preservative System Efficacy against Pseudomonas aeruginosa and Burkholderia cepacia Noa Ziklo, Inbal Tzafrir, Regina Shulkin and Paul Salama * Innovation department, Sharon Laboratories Ltd., Odem St. Industrial zone Ad-Halom, Ashdod 7898800, Israel; [email protected] (N.Z.); [email protected] (I.T.); [email protected] (R.S.) * Correspondence: [email protected]; Tel.: +972-54-2166476 Received: 15 July 2020; Accepted: 1 August 2020; Published: 3 August 2020 Abstract: Contamination of personal-care products are a serious health concern and therefore, preservative solutions are necessary for the costumers’ safety. High sun protection factor (SPF) sunscreen formulations are known to be difficult to preserve, due to their high ratio of organic phase containing the UV-filters. Salicylate esters such as octyl salicylate (OS) and homosalate (HS) are among the most common UV-filters currently used in the market, and can undergo hydrolysis by esterase molecules produced by contaminant microorganisms. The hydrolysis product, salicylic acid (SA) can be assimilated by certain bacteria that contain the chorismate pathway, in which its final product is pyochelin, an iron-chelating siderophore. Here, we show that OS and HS can compromise the preservative efficacy against two pathogenic important bacteria, Pseudomonas aeruginosa and Burkholderia cepacia. Challenge tests of formulations containing the UV-filters demonstrated that only bacteria with the chorismate pathway failed to be eradicated by the preservation system. mRNA expression levels of the bacterial pchD gene, which metabolizes SA to produce pyochelin, indicate a significant increase that was in correlation with increasing concentrations of both OS and HS.
    [Show full text]
  • Cutaneous Permeation and Penetration of Sunscreens: Formulation Strategies and in Vitro Methods
    cosmetics Review Cutaneous Permeation and Penetration of Sunscreens: Formulation Strategies and In Vitro Methods Silvia Tampucci * ID , Susi Burgalassi ID , Patrizia Chetoni ID and Daniela Monti ID Department of Pharmacy, University of Pisa, 56126 Pisa, Italy; [email protected] (S.B.); [email protected] (P.C.); [email protected] (D.M.) * Correspondence: [email protected] Received: 1 November 2017; Accepted: 7 December 2017; Published: 25 December 2017 Abstract: Sunscreens are the most common products used for skin protection against the harmful effects of ultraviolet radiation. However, as frequent application is recommended, the use of large amount of sunscreens could reflect in possible systemic absorption and since these preparations are often applied on large skin areas, even low penetration rates can cause a significant amount of sunscreen to enter the body. An ideal sunscreen should have a high substantivity and should neither penetrate the viable epidermis, the dermis and the systemic circulation, nor in hair follicle. The research of methods to assess the degree of penetration of solar filters into the skin is nowadays even more important than in the past, due to the widespread use of nanomaterials and the new discoveries in cosmetic formulation technology. In the present paper, different in vitro studies, published in the last five years, have been reviewed, in order to focus the attention on the different methodological approaches employed to effectively assess the skin permeation and retention of sunscreens. Keywords: sunscreens; formulation; in vitro methods; cutaneous permeation; skin penetration 1. Introduction The detrimental effects of human exposure to ultraviolet (UV) radiation have been widely investigated and can be immediate, as in the case of sunburns, or long-term, causing, in most cases, the formation of oxidizing species responsible of photo-aging, immunosuppression and chronic effects such as photo carcinogenicity [1,2].
    [Show full text]